OncoImmunology (Jan 2020)

Destroy, what destroys you

  • Khang Luu,
  • Emily Nickles,
  • Herbert Schwarz

DOI
https://doi.org/10.1080/2162402X.2019.1685301
Journal volume & issue
Vol. 9, no. 1

Abstract

Read online

New evidence indicates the importance of CD137 for controlling Epstein-Barr virus (EBV) infections. (1) Mutations in CD137 predispose to EBV-associated diseases. (2) EBV induces ectopic CD137 expression, thereby activating a negative feed-back regulation and reducing T cell costimulation. These findings suggest CD137 agonists as new treatments for EBV-associated diseases.

Keywords